Recently Featured

Mapp, Gilead Antivirals to Be Deployed in DRC Ebola Trial: WHO Chief

July 6, 2026
The World Health Organization has announced plans to evaluate Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir in a clinical trial targeting the Bundibugyo ebolavirus in the Democratic Republic of the Congo. This initiative marks a significant step in the ongoing battle against Ebola, particularly as the region faces recurrent outbreaks of the virus. The deployment…

Pfizer scores 1st expansion in 7 years for breast cancer blockbuster Ibrance

July 6, 2026
Pfizer has achieved a significant milestone with the first expansion of its breast cancer treatment, Ibrance, in seven years, as it has been approved for use as a maintenance therapy in HR+/HER2+ breast cancer. This development marks a pivotal moment for the company, which has been navigating a competitive oncology landscape while seeking to enhance…

Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal

July 5, 2026
Novartis has announced a strategic acquisition of Antares Therapeutics for $1.9 billion, aiming to bolster its oncology portfolio by targeting cancers previously deemed undruggable. This significant investment underscores Novartis’s commitment to advancing precision medicine and addressing unmet medical needs in oncology. The deal comes at a time when the pharmaceutical industry is increasingly focused on…

Ollin refuels with $330M to back pivotal tests of Vabysmo challenger

July 5, 2026
Ollin Biosciences has secured $330 million in one of the year’s largest venture funding rounds, positioning itself to advance pivotal clinical trials for its ophthalmic treatment, a direct competitor to Roche’s Vabysmo. This funding follows the recent release of a head-to-head study that demonstrated Ollin’s drug, licensed from a developer in China, possesses certain advantages…

Ongoing Cases